EverHint – EMA 10 + Price + MACD – Top 7 Signals for Aug 17, 2026

Excerpt: 7 signals. Healthcare leads (2). price range $12-$1051.

What This Signal Is

Experimental strategy combining price crossing above EMA10 from below with MACD Line crossing above Signal Line from below. Both conditions must occur on the same day for a signal, providing double confirmation and higher-quality setups.

Entry Criteria:

• Buy: Price > EMA10 AND MACD line crosses above signal line
• Sell: Price < EMA10 AND MACD line crosses below signal line
• Minimum ADV: $40M (liquidity filter)
• Earnings buffer: 7 days pre/post earnings
• Fresh signal: All conditions met on today's close

Holding period: 1-3 weeks | Risk level: Medium-High

Market Context

Equity markets are experiencing a modest broad-based pullback, with all three major indices declining roughly half a percent on the session. While the magnitude of the decline remains contained, the VIX's sharp 6.60% jump to 15.19 signals a meaningful uptick in near-term uncertainty. This volatility expansion can widen intraday price swings, which tends to generate both more frequent crossover signals and a higher rate of false positives for momentum-based strategies like EMA/MACD combinations. Traders should be aware that entry triggers may require slightly wider confirmation windows in this environment.

The simultaneous decline across the S&P 500, Nasdaq, and Dow Jones suggests broad risk-off sentiment rather than sector-specific rotation, which moderates overall risk appetite. For EMA-price and MACD crossover signals, a trending environment is ideal — but today's uniform selling pressure indicates the market may be consolidating or correcting rather than establishing a clean directional trend. This can compress the reliability of trend-following signals in the short term, making signal quality and confirmation particularly important before acting.

Healthcare emerging as the top signal-generating sector is notable in this context, as defensive sectors like Healthcare historically attract capital during periods of elevated uncertainty and softening risk appetite. The VIX spike aligns with this rotation dynamic, suggesting investors may be repositioning toward more resilient, lower-beta areas of the market. Signals originating from Healthcare in this environment may carry a more favorable risk profile than those from high-beta sectors, as the defensive rotation provides a macro tailwind that can support trend continuation setups.

🟢 Buy Signals (7 of 7 total)

Ranked by RSI (lower RSI = more oversold for buy signals)

Field Notes

Sector concentration: Healthcare (2), Industrials (2), Financial Services (2)

Data coverage: 0.0% insider (7d), 0.0% congressional (30d), 0.0% earnings, 42.9% news (7d)

Peer Analysis

CMI (Cummins Inc.): Leads 5 peers: ITW ($287.28), CNI ($126.59), ROP ($389.71), FDX ($331.49), NSC ($341.12)

XPEV (XPeng Inc.): Leads 5 peers: LI ($12.41), NIO ($4.60), PHM ($128.49), RIVN ($14.87), ULTA ($493.33)

FUTU (Futu Holdings Limited): Leads 5 peers: BTBT ($1.60), XP ($15.70), APLD ($31.18), RIOT ($20.04), MARA ($9.71)

GS (The Goldman Sachs Group, Inc.): Leads 5 peers: MS ($218.21), HSBC ($103.80), AXP ($336.21), RY ($216.19), SCHW ($110.58)

CAR (Avis Budget Group, Inc.): Leads 5 peers: HRI ($173.12), LNZA ($6.30), ALK ($44.04), BCO ($111.28), OMAB ($102.79)

Recent Headlines

ARGX (argenx SE)

• argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing
• Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
• Argenx says efgartigimod met main goal in myositis trial

CAR (Avis Budget Group, Inc.)

• ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Avis Budget Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Against Pentwater Capital Management LP - CAR
• Bronstein, Gewirtz & Grossman LLC Urges Avis Budget Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
• Avis Budget Group, Inc. Notice of September 29, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
• CAR Investor Alert: Pentwater Capital Management LP Securities Class Action Notice - Contact Levi & Korsinsky
• Kaplan Fox Urges Investors of Avis Budget Group, Inc. (CAR) with Significant Losses to Seek a Leadership Role Before September 29, 2026

XPEV (XPeng Inc.)

• XPeng Inc (XPEV) Shares Surge 4.3% -- What GF Score of 62 Tells Investors
• EV, Battery Sales Help Q2 Cleantech Investment Rebound

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/

📢 Support the project by liking, sharing, or subscribing — it helps more readers discover these signals.